Literature DB >> 31312989

Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity.

Itzel Viridiana Reyes-Pérez1, Pedro Ernesto Sánchez-Hernández2, José Francisco Muñoz-Valle3, Gloria Esther Martínez-Bonilla4, Trinidad García-Iglesias1, Verónica González-Díaz4, Samuel García-Arellano3, Sergio Cerpa-Cruz4, Julissa Polanco-Cruz4, María Guadalupe Ramírez-Dueñas5.   

Abstract

INTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial membrane damage and autoantibody production. RA is a heterogeneous disease, where cytokines such as IL-15, IL-21, and IFN-γ have been associated. However, their association with the autoantibodies has not been clearly described. The aim of this study was to evaluate the relationship between the cytokines IL-15, IL-21, and IFN-γ with the autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) in RA and disease activity.
METHODOLOGY: This study included 153 RA patients and 80 control subjects (CS). The levels of IL-15, IL-21, IFN-γ, anti-CCP, anti-MCV, and anti-PADI4 were quantified by ELISA, whereas RF was quantified by turbidimetry. The disease activity was evaluated by the indices disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR), clinical disease activity index (CDAI), and simple disease activity index (SDAI).
RESULTS: The serum levels of IL-15, IL-21, and IFN-γ, and autoantibodies were increased in RA patients, compared with CS (p < 0.05). A correlation was found between IL-21 and anti-CCP and anti-MCV (p < 0.05). According to RA evolution, RF, anti-CCP, and anti-MCV had higher levels in early RA. In addition, increased levels of IL-21 were observed in RA seropositive patients (RF/anti-CCP/anti-MCV). The higher levels of both cytokines and autoantibodies were observed in moderate activity, evaluated by the three indices.
CONCLUSIONS: Our results suggest that the increased soluble levels of IL-15, IL-21, and IFN-γ are involved in the inflammatory network in RA. However, IL-21 serum levels are associated with higher titers of autoantibodies (RF, anti-CCP, and anti-MCV) and IL-15 with moderate activity. Key Points • IL-15, IL-21, and IFN-y are associated with the immunopathology of RA, but not significantly with the evolution of the disease. • RF, anti-CCP, and anti-MCV had higher levels in early than established RA. • IL-21 has an association with RF, anti-CCP, and anti-MCVand, for this reason, could be proposed as a disease biomarker. • Patients with activity moderate of disease showed higher levels of RF, anti-CCP, anti-MCV, and IL-15.

Entities:  

Keywords:  Anti-CCP; Anti-MCV; Autoantibodies; Cytokines; Rheumatoid arthritis

Year:  2019        PMID: 31312989     DOI: 10.1007/s10067-019-04681-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  55 in total

1.  Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis.

Authors:  Tue Kruse Rasmussen; Thomas Andersen; Malene Hvid; Merete Lund Hetland; Kim Hørslev-Petersen; Kristian Stengaard-Pedersen; Christian Kanstrup Holm; Bent Deleuran
Journal:  J Rheumatol       Date:  2010-08-03       Impact factor: 4.666

2.  Circulating cytokine pattern and factors describing rheumatoid arthritis: IL-15 as one of the biomarkers for RA?

Authors:  Monika Pavkova Goldbergova; Nikolas Pavek; Jolana Lipkova; Jiri Jarkovsky; Martina Stouracova; Jindra Gatterova; Anna Vasku; Miroslav Soucek; Petr Nemec
Journal:  Biomarkers       Date:  2012-09-24       Impact factor: 2.658

Review 3.  The role of IL-21 in immunity and cancer.

Authors:  Matthew R Davis; Ziwen Zhu; Dwayne M Hansen; Qian Bai; Yujiang Fang
Journal:  Cancer Lett       Date:  2015-01-06       Impact factor: 8.679

4.  Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.

Authors:  Manathip Osiri; Jongkonnee Wongpiyabovorn; Youwanuch Sattayasomboon; Niramol Thammacharoenrach
Journal:  Clin Rheumatol       Date:  2016-05-17       Impact factor: 2.980

Review 5.  IL-21 as a therapeutic target in inflammatory disorders.

Authors:  Davide Di Fusco; Roberta Izzo; Michele M Figliuzzi; Francesco Pallone; Giovanni Monteleone
Journal:  Expert Opin Ther Targets       Date:  2014-08-27       Impact factor: 6.902

Review 6.  New biomarkers in rheumatoid arthritis.

Authors:  A Willemze; R E M Toes; T W J Huizinga; L A Trouw
Journal:  Neth J Med       Date:  2012-11       Impact factor: 1.422

Review 7.  The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis.

Authors:  A A Jilani; C G Mackworth-Young
Journal:  Int J Rheumatol       Date:  2015-03-04

8.  The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis.

Authors:  A S Avdeeva; E N Aleksandrova; A A Novikov; A V Smirnov; M V Cherkasova; E L Nasonov
Journal:  Int J Rheumatol       Date:  2014-04-15

9.  The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis.

Authors:  Isabela Siloşi; Mihail Virgil Boldeanu; Manole Cojocaru; Viorel Biciuşcă; Vlad Pădureanu; Maria Bogdan; Ramona Georgiana Badea; Carmen Avramescu; Ileana Octavia Petrescu; Florin Petrescu; Cristian A Siloşi
Journal:  J Immunol Res       Date:  2016-08-04       Impact factor: 4.818

10.  Cigarette Smoke Induces Immune Responses to Vimentin in both, Arthritis-Susceptible and -Resistant Humanized Mice.

Authors:  Mitali Bidkar; Robert Vassallo; David Luckey; Michele Smart; Kelly Mouapi; Veena Taneja
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

View more
  7 in total

Review 1.  Follicular helper T cells: potential therapeutic targets in rheumatoid arthritis.

Authors:  Jian Lu; Jing Wu; Xueli Xia; Huiyong Peng; Shengjun Wang
Journal:  Cell Mol Life Sci       Date:  2021-04-20       Impact factor: 9.261

2.  Could IL-1β, IL-6, IFN-γ, and sP-selectin serum levels be considered as objective and quantifiable markers of rheumatoid arthritis severity and activity?

Authors:  Olga M Koper-Lenkiewicz; Ewa Gińdzieńska-Sieśkiewicz; Joanna Kamińska; Anna J Milewska; Otylia Kowal-Bielecka; Joanna Matowicka-Karna
Journal:  Reumatologia       Date:  2022-02-28

Review 3.  Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis.

Authors:  Jie Huang; Xuekun Fu; Xinxin Chen; Zheng Li; Yuhong Huang; Chao Liang
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

4.  Th17/Treg-Related Transcriptional Factor Expression and Cytokine Profile in Patients With Rheumatoid Arthritis.

Authors:  Agnieszka Paradowska-Gorycka; Anna Wajda; Katarzyna Romanowska-Próchnicka; Ewa Walczuk; Ewa Kuca-Warnawin; Tomasz Kmiolek; Barbara Stypinska; Ewa Rzeszotarska; Dominik Majewski; Pawel Piotr Jagodzinski; Andrzej Pawlik
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

Review 5.  Activities and Molecular Mechanisms of Diterpenes, Diterpenoids, and Their Derivatives in Rheumatoid Arthritis.

Authors:  Muhammad Torequl Islam; Cristina Quispe; Jesús Herrera-Bravo; Md Mizanur Rahaman; Rajib Hossain; Chandan Sarkar; Md Abdur Raihan; Md Mashrur Chowdhury; Shaikh Jamal Uddin; Jamil A Shilpi; João Marcelo de Castro E Sousa; Ana Amélia de Carvalho Melo-Cavalcante; Mohammad S Mubarak; Javad Sharifi-Rad; Daniela Calina
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

Review 6.  The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review.

Authors:  Yuki Ishikawa; Chikashi Terao
Journal:  Cells       Date:  2020-02-19       Impact factor: 6.600

7.  Acquisition of New Migratory Properties by Highly Differentiated CD4+CD28null T Lymphocytes in Rheumatoid Arthritis Disease.

Authors:  Beatriz Rioseras; Marco Antonio Moro-García; Alejandra García-Torre; Eva Bueno-García; Rocio López-Martínez; Maria Iglesias-Escudero; Roberto Diaz-Peña; Patricia Castro-Santos; Miguel Arias-Guillén; Rebeca Alonso-Arias
Journal:  J Pers Med       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.